Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

No abstract is available for this paper.

• Publication year

  2003

• Venue

  HYPERTENSION

• Publication date

  2003-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.HYP.0000044937.95080.E9PMID 12511531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure.

  2002cited by this paper
• Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.

  2001cited by this paper
• High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.

  2001cited by this paper
• Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.

  2001cited by this paper
• Aldosterone Escape during Angiotensinconverting Enzyme Inhibitor Therapy in Essential Hypertensive Patients with Left Ventricular Hypertrophy

  2001cited by this paper
• Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.

  2001cited by this paper
• O-25: Local angiotensin II and transforming growth factor-beta 1 in renal fibrosis of rats

  2001cited by this paper
• Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift

  2001cited by this paper
• Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

  2000cited by this paper
• Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients.

  2000cited by this paper
• Guidelines for the management of hypertension.

  2000cited by this paper
• Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats.

  2000cited by this paper
• Effects of spironolactone on systolic blood pressure in experimental diabetic rats.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

  1999cited by this paper
• A critique of the world health organization-international society of hypertension guidelines for the management of hypertension

  1999cited by this paper
• Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

  1999cited by this paper
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

  1997cited by this paper
• Aldosterone, salt and cardiac fibrosis.

  1997cited by this paper
• The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (NIH Publication No. 98-4080)

  1997cited by this paper
• High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes.

  1996cited by this paper
• Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.

  1996cited by this paper
• Evidence of a Partial Escape of Renin‐Angiotensin‐Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors

  1993cited by this paper
• Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

  1992cited by this paper
• Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.

  1987cited by this paper
• Use of single voided urine samples to estimate quantitative proteinuria.

  1983cited by this paper
• Increase in plasma aldosterone during prolonged captopril treatment.

  1982cited by this paper
• Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.

  1981cited by this paper
• Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements

  1978cited by this paper
• Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method

  1977cited by this paper
• Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro.

  1961cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy*

  year unknowncited by this paper

• Diagnosis and treatment of diabetic nephropathy (C3a and C3b stages)

  2025cites this paper
• Use of finerenone in patients with chronic kidney disease at high risk of heart failure.

  2025cites this paper
• Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD

  2025cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.

  2025cites this paper
• Factors Influencing the Efficacy of Low-Dose Spironolactone in Adults with Chronic Kidney Disease and Type 2 Diabetes: A post hoc Analysis

  2025cites this paper
• Innovative therapeutics for renoprotection: Where we are.

  2025cites this paper
• Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?

  2025cites this paper
• Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists

  2024cites this paper
• Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity

  2024cites this paper
• Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

  2024cites this paper
• Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

  2024cites this paper
• Inhibition of intrarenal PRR-RAS pathway by Ganoderma lucidum polysaccharide peptides in proteinuric nephropathy.

  2023cites this paper
• Mineralocorticoid receptor antagonists in cardiovascular translational biology

  2023cites this paper
• Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists

  2023cites this paper
• Slowing the Progression of Diabetic Kidney Disease

  2023cites this paper
• Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx

  2023cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cites this paper
• Maladie rénale chronique et diabète de type 2. Histologie, pathogénie et stades évolutifs

  2023cites this paper
• Therapeutic perspective-evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.

  2023cites this paper
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

  2023cites this paper
• Aldosterone: Essential for Life but Damaging to the Vascular Endothelium

  2023cites this paper
• Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus.

  2023cites this paper
• Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes.

  2023cites this paper
• Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2022cites this paper
• Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future

  2022cites this paper
• The spectrum of plasma renin activity and hypertension diseases: Utility, outlook, and suggestions

  2022cites this paper
• Aldosterone breakthrough from a pharmacological perspective

  2022cites this paper
• Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes

  2022cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.

  2022cites this paper
• Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist

  2022cites this paper
• Aldosterone in chronic kidney disease and renal outcomes.

  2022cites this paper
• The Diabetic Cardiorenal Nexus

  2022cites this paper
• Increased glucocorticoid metabolism in diabetic kidney disease

  2022cites this paper
• Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists

  2022cites this paper
• Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes

  2022cites this paper
• Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021

  2022cites this paper
• Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

  2022cites this paper
• Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy

  2022influential citation
• Glomerular Mesangial Cell pH Homeostasis Mediates Mineralocorticoid Receptor-Induced Cell Proliferation

  2021cites this paper
• Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease

  2021cites this paper
• Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

  2021cites this paper
• Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

  2021cites this paper
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2021cites this paper
• Systematic Review and Meta-Analysis of Renin–Angiotensin–Aldosterone System Blocker Effects on the Development of Cardiovascular Disease in Patients With Chronic Kidney Disease

  2021cites this paper
• Budućnost antagonista mineralokortikoidnih receptora u liječenju dijabetičke nefropatije Future of Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Nephropathy

  2021cites this paper
• Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension

  2020cites this paper
• A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy

  2020cites this paper
• Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.

  2020cites this paper
• The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial

  2020cites this paper
• Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone

  2020cites this paper
• Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease

  2020influential citation
• Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease

  2020cites this paper
• Controversy over renin–angiotensin–aldosterone system (RAAS) inhibitors treatment in nephrology and cardiovascular diseases

  2020cites this paper
• Approach to Chronic Kidney Disease in the Diabetic Patient

  2020cites this paper
• A Pilot Trial on the Effect of Levothyroxine on Proteinuria in Patients With Advanced CKD

  2020cites this paper
• The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic 
Nephropathy

  2019cites this paper
• Histone demethylase LSD1 deficiency and biological sex: impact on blood pressure and aldosterone production.

  2019cites this paper
• The role of aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?

  2019cites this paper
• Anti-Albuminuric Effects of Spironolactone In Type-2 Diabetic Nephropathy

  2019cites this paper
• Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.

  2019cites this paper
• SPIRONOLACTONEALONG WITH RAMIPRIL DIABETIC NEPHROPATHY

  2019cites this paper
• The renin‐angiotensin‐aldosterone system and its suppression

  2019cites this paper
• Effect on serum potassium level in patients of diabetic nephropathy on spironolactone and ramipril over follow up period

  2019cites this paper
• Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

  2019cites this paper
• Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis

  2019cites this paper
• Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?

  2019cites this paper
• Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study

  2019cites this paper
• Mineralocorticoid Antagonism and Diabetic Kidney Disease

  2019cites this paper
• Membranous Lupus Nephritis: A Clinical Review.

  2019cites this paper
• Spironolactone in the treatment of hypertension: a neglected molecule.

  2018cites this paper
• Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives.

  2018cites this paper
• Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis

  2018cites this paper
• Treatment Goals in Diabetic Nephropathy

  2018cites this paper
• Future and Novel Compounds in the Treatment of Diabetic Nephropathy

  2018cites this paper
• Cardiac hypertrophy in chronic kidney disease—role of Aldosterone and FGF23

  2018cites this paper
• The Impact of Cardiovascular Drugs on Diabetes: A review

  2018cites this paper
• 1 Up-Regulation of Renin-Angiotensin System in Diabetes and Hypertension : Implications on the Development of Diabetic Nephropathy

  2018cites this paper
• Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial

  2018cites this paper
• Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease

  2018cites this paper
• A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

  2017cites this paper
• THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.

  2017cites this paper
• 24 Blood Pressure Control in Patients with Glomerulonephritis

  2017cites this paper
• Rôle de la Neutrophil Gelatinase-Associated Lipocalin dans les effets cardiovasculaires et rénaux de l'activation du récepteur minéralocorticoïde. Spécificité et mécanismes d’action

  2017cites this paper
• Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension

  2017cites this paper
• PREVALENCE AND MANAGEMENT OF DIABETIC NEPHROPATHY : Diabetic nephropathy, End-Stage-Renal-Disease, Hypertension, ACE inhibitors, Urine protein,

  2017cites this paper
• Effects of Treating Primary Aldosteronism on Renal Function

  2017cites this paper
• DRUGS FOR DIABETIC NEPHROPATHY- FULL REVIEW

  2017cites this paper
• The Role of Aldosterone in Obesity-Related Hypertension.

  2016cites this paper
• Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients

  2016cites this paper
• Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety

  2016cites this paper
• Study of Chronic Kidney Disease in Geriatric Population: Etiology, Clinical Profile and Outcome

  2016cites this paper
• The association between albuminuria and long-term renal risk: How to improve the precision of drug effect estimates

  2016cites this paper
• Reducing cardiovascular risk in chronic kidney disease : a focus on mineralocorticoid receptor antagonist and arterial stiffness in primary care

  2016cites this paper
• Global cardiovascular protection in chronic kidney disease

  2016cites this paper
• HIPERTENSIÓN ARTERIAL, N EFROPATÍA DIABÉTICA Y RIESGO CARDIOVASCULAR

  2016cites this paper
• Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

  2016cites this paper
• Transforming growth factor-β1 and diabetic nephropathy.

  2016cites this paper
• Individual long-term albuminuria exposure during ARB therapy is the optimal predictor for renal outcome

  2016cites this paper
• Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.

  2016cites this paper